Dendreon Antigen definition

Dendreon Antigen means an antigen that is claimed by a patent or is otherwise covered by intellectual property rights that are Controlled by Dendreon.
Sample 1Sample 2Sample 3

Examples of Dendreon Antigen in a sentence

  • Kirin and its Affiliates shall not resell the Separation Devices purchased pursuant to this Article 2 except as part of a Kirin Product or a Licensed Dendreon Product, and shall not use Separation Devices, Reagents or Dendreon Antigen for any purpose other than those purposes permitted in this Agreement, the Collaborative License Agreement or the Research and License Agreement.

  • In the absence of Kirin's exercise of the Kirin PA2024 Option, Dendreon's obligation to furnish Kirin with Dendreon Antigen PA2024 shall continue to be as set forth in this Agreement.

  • However, Dendreon's duty to sell to Kirin quantities of Dendreon Antigen PA2024 shall terminate three (3) years after the date Kirin exercises the Kirin PA2024 Option and receives Dendreon PA2024 Manufacturing Technology for the manufacture of PA2024 under Section 2.5 of the Collaborative License Agreement.

  • Within thirty (30) days after each exercise of the Dendreon PA2024 Option under Section 2.4(d) (for a license of Kirin's PA2024 Manufacturing Improvements for the manufacture of Dendreon Antigen PA2024), Dendreon shall pay Kirin an amount in U.S. Dollars equal to ninety percent 90% of Kirin's Cost, but limited to the development cost of such Kirin PA2024 Manufacturing Improvements and with a credit to Dendreon for payments previously made under prior exercises of the option (if any).

  • Within thirty (30) days after each exercise of the Dendreon PA2024 Option under Section 2.4(d) (for a license of Kirin's PA2024 Manufacturing Improvements for the manufacture of Dendreon Antigen PA2024), Dendreon shall pay Kirin an amount in U.S. Dollars equal to ninety percent 90% of Kirin's Cost, but limited to the development cost of such Kirin PA2024 Manufacturing Improvements and with a credit to 34.

  • Dendreon hereby grants to Kirin an exclusive option (the "Kirin PA2024 Option") to obtain a fully paid up, non-exclusive license, with the right to sublicense under Dendreon PA2024 Manufacturing Technology to manufacture Dendreon Antigen PA2024 (which is a Dendreon Component) as provided in this Section 2.5. A statement of Dendreon PA2024 Manufacturing Technology is attached hereto in the illustrative flow chart in Schedule 2.5 and made a part hereof.

  • Thereafter, but only during the period when Purchaser is permitted hereunder to exercise the Back-Up License, Purchaser shall be permitted access to and a right of reference to any Regulatory Approvals held in Supplier's name for the Kirin Antigen or Dendreon Antigen that is the subject of such Back-Up License.

  • This Warrant may be transferred in whole or in part by the Holder at any time, subject to the limitations set forth in this Article II.

  • If, despite good faith efforts, the senior management officials are unable to reach agreement on the resolution of such supply problem within twenty (20) days of their commencing such discussions, then at either Party's immediate written request, the problem will be governed by the terms of Section 11.7 if it affects Components other than Kirin Antigen or Dendreon Antigen, and by the terms of Section 3.7(c) if it affects Kirin Antigen or Dendreon Antigen.

Related to Dendreon Antigen

  • Antigen means a substance recognized by the body as being foreign; it results in the production of specific antibodies directed against it.

  • Antibody means a molecule comprising or containing one or more immunoglobulin variable domains or any fragments, derivatives, variants or modifications thereof that bind to the same antigen.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Licensed Compound means [***].

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Product Candidate means any pharmaceutical product developed, manufactured and/or tested by or on behalf of the Company that has not received a Regulatory Authorization for commercial distribution other than in connection with pre-clinical or clinical trials.

  • Biosimilar Product means, with respect to a Licensed Product and on a country-by-country basis, a product that [***].

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Licensed Compounds means: (a) Research Program Active Compounds; (b) Novartis Active Compounds; (c) salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers and polymorphs of Research Program Active Compounds or Novartis Active Compounds; and (d) prodrugs of Research Program Active Compounds or Novartis Active Compounds (any of the foregoing, a “Licensed Compound”).

  • Biological Samples means any physical samples obtained from Study Participants in accordance with the Protocol for the purposes of the Study.

  • Active Pharmaceutical Ingredient or “API” shall mean one or more of the following active pharmaceutical ingredients: tenofovir alafenamide (“TAF”), tenofovir disoproxil fumarate (“TDF”), elvitegravir (“EVG”), and cobicistat (“COBI”).

  • GSK has the meaning set forth in the preamble.

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Manufacturing Technology means any and all patents, patent applications, know-how, and all intellectual property rights associated therewith that are owned or controlled by Licensor, and including all tangible embodiments thereof, that are necessary or useful for the manufacture of adeno-associated viruses, adeno-associated virus vectors, research or commercial reagents related thereto, Licensed Products, or other products, including manufacturing processes, technical information relating to the methods of manufacture, protocols, standard operating procedures, batch records, assays, formulations, quality control data, specifications, scale up, any and all improvements, modifications, and changes thereto, and any and all activities associated with such manufacture. Any and all chemistry, manufacturing, and controls (CMC), drug master files (DMFs), or similar materials provided to regulatory authorities and the information contained therein are deemed Manufacturing Technology.

  • Collaborating physician means the physician who,

  • Biosimilar means a biological product that is highly similar to a specific reference biological

  • Aerosol coating product means a pressurized coating product containing pigments or resins that dispenses product ingredients by means of a propellant, and is packaged in a disposable can for hand-held application, or for use in specialized equipment for ground traffic/marking applications.

  • in vitro diagnostic medical device means any medical device which is a reagent, reagent product, calibrator, control material, kit, instrument, apparatus, equipment, software or system, whether used alone or in combination, intended by the manufacturer to be used in vitro for the examination of specimens, including blood and tissue donations, derived from the human body, solely or principally for the purpose of providing information:

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • orphan means a child who has no surviving parent caring for him or her;

  • Diagnostic Product means any test or assay for diagnosing or detecting a disease, disorder, medical condition, or symptom.

  • Drug Substance means an active ingredient that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the human body, but does not include intermediates used in the synthesis of such ingredient.

  • BMS means the Company, all related companies, affiliates, subsidiaries, parents, successors, assigns and all organizations acquired by the foregoing.

  • Compound means the taking of two or more ingredients and fabricating them into a single

  • Biological product means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein other than a chemically synthesized polypeptide, or analogous product, or arsphenamine or any derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human beings.